Serum Institute CEO sees AstraZeneca’s COVID-19 vaccine as “very good” candidate By Reuters

© Reuters. FILE PHOTO: Outbreak of the coronavirus disease (COVID-19) in Pune

By Euan Rocha and Nidhi Verma

MUMBAI/NEW DELHI (Reuters) – Serum Institute of India, the world’s largest vaccine producer, sees AstraZeneca (NASDAQ:) Plc’s COVID-19 vaccine candidate as a “very good” option, giving it a major vote of confidence after some experts raised questions around its trial data.

Serum Institute of India (SII), which has partnered with the British drugmaker to conduct trials on its COVISHIELD vaccine in India and produce the vaccine candidate if it secures approval, plans to apply for an emergency use licence for the vaccine in the next two weeks, said SII’s Chief Executive Adar Poonawalla.

“This vaccine is a very good one,” said Poonawalla, via a virtual press briefing following Indian Prime Minister Narendra Modi’s visit to SII’s campus on Saturday.

“What we found with COVISHIELD in its global trial is there were zero hospitalisations, which means even if you do get infected you’re not going to have a severe attack and secondly even those who got the disease were not infecting others,” he said.

Poonawalla’s comments come as a boost to AstraZeneca after some scientists raised doubts about the robustness of results showing the shot was 90% effective in a sub-group of trial participants who, by error initially, received a half dose followed by a full dose.

He also noted that the AstraZeneca vaccine, along with the vaccine from Novavax (NASDAQ:) – the U.S. vaccine developer that SII has also partnered with – offered a significant edge over the vaccine candidates of certain rivals, which need to be stored at much lower temperatures.

“Both our vaccine candidates can be stored in 2 Celsius to 8 Celsius and India has lot of storage and infrastructure for that temperature range. It has slightly less storage capacity for -20 C and almost nothing for -70 C,” said Poonawalla.

U.S. vaccine developers Moderna (NASDAQ:) and Pfizer (NYSE:) recently announced strong efficacy results on their respective vaccine candidates, but both of their vaccines need to be stored at very low temperatures that would present challenges for many developing economies.

Moderna has said its vaccine can be stored at normal fridge temperatures of 2 to 8 degrees Celsius for 30 days and it can be stored for up to 6 months at -20C. Pfizer’s experimental vaccine must be stored at -70C over longer durations.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Be the first to comment

Leave a Reply

Your email address will not be published.


*